Ind-Swift Ltd
Incorporated in 1986, Ind-Swift Ltd deals in manufacturing and exporting of pharmaceutical products
- Market Cap ₹ 114 Cr.
- Current Price ₹ 21.4
- High / Low ₹ 31.2 / 7.65
- Stock P/E
- Book Value ₹ -132
- Dividend Yield 0.00 %
- ROCE 8.28 %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.78% over past five years.
- Promoters have pledged 42.8% of their holding.
- Earnings include an other income of Rs.78.3 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Jun 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,590 | 393 | 570 | 417 | 308 | 263 | 270 | 289 | 330 | 356 | 398 | 411 | 473 | |
1,494 | 411 | 602 | 487 | 465 | 328 | 262 | 278 | 306 | 315 | 352 | 369 | 431 | |
Operating Profit | 97 | -18 | -32 | -70 | -157 | -65 | 8 | 11 | 23 | 41 | 45 | 42 | 42 |
OPM % | 6% | -4% | -6% | -17% | -51% | -25% | 3% | 4% | 7% | 12% | 11% | 10% | 9% |
24 | 2 | 11 | 2 | 13 | -246 | -20 | 34 | 22 | 14 | 24 | 72 | 78 | |
Interest | 121 | 86 | 77 | 40 | 19 | 16 | 7 | 3 | 29 | 52 | 57 | 60 | 63 |
Depreciation | 23 | 18 | 26 | 39 | 36 | 36 | 35 | 34 | 34 | 33 | 32 | 29 | 27 |
Profit before tax | -24 | -121 | -124 | -147 | -200 | -363 | -53 | 8 | -17 | -29 | -20 | 26 | 30 |
Tax % | 12% | 8% | 7% | 2% | -0% | -0% | -1% | -0% | -15% | -1% | -2% | -0% | |
-21 | -111 | -116 | -145 | -200 | -364 | -54 | 8 | -19 | -30 | -20 | 26 | 30 | |
EPS in Rs | -4.55 | -24.10 | -22.95 | -28.83 | -39.71 | -67.25 | -9.99 | 1.51 | -3.53 | -5.51 | -3.70 | 4.81 | 5.50 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 9% |
3 Years: | 8% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 5% |
5 Years: | -9% |
3 Years: | -14% |
TTM: | 5% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 32% |
3 Years: | 76% |
1 Year: | 153% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Jun 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9 | 9 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
Reserves | 295 | 194 | 84 | -64 | -264 | -636 | -690 | -688 | -724 | -706 | -731 | -716 | -724 |
Preference Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | |
819 | 971 | 1,010 | 1,040 | 1,047 | 1,048 | 1,041 | 996 | 1,003 | 1,008 | 1,021 | 978 | 976 | |
446 | 233 | 286 | 242 | 268 | 246 | 251 | 279 | 312 | 358 | 331 | 376 | 376 | |
Total Liabilities | 1,568 | 1,407 | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 632 | 649 | 639 |
396 | 421 | 440 | 404 | 374 | 342 | 311 | 291 | 270 | 244 | 236 | 216 | 205 | |
CWIP | 49 | 37 | 4 | 4 | 4 | 2 | -0 | -0 | -0 | 13 | 9 | 30 | 35 |
Investments | 46 | 45 | 45 | 45 | 45 | 44 | 44 | 41 | 24 | 70 | 64 | 54 | 54 |
1,077 | 905 | 900 | 775 | 638 | 281 | 258 | 267 | 308 | 344 | 323 | 349 | 346 | |
Total Assets | 1,568 | 1,407 | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 632 | 649 | 639 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Jun 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
94 | -146 | 103 | 86 | -106 | 7 | 1 | 43 | 35 | 83 | 50 | 73 | |
-184 | -28 | -14 | -6 | -4 | -4 | -3 | -14 | -11 | -17 | -18 | -29 | |
99 | 146 | -89 | -81 | 110 | -11 | -4 | -13 | -26 | -54 | -45 | -47 | |
Net Cash Flow | 9 | -28 | 0 | -1 | 0 | -8 | -5 | 16 | -3 | 12 | -13 | -3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Jun 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 103 | 338 | 282 | 425 | 451 | 151 | 113 | 95 | 104 | 111 | 83 | 93 |
Inventory Days | 98 | 418 | 202 | 117 | 151 | 86 | 108 | 112 | 102 | 123 | 120 | 150 |
Days Payable | 90 | 179 | 152 | 155 | 290 | 356 | 426 | 454 | 440 | 454 | 353 | 393 |
Cash Conversion Cycle | 112 | 577 | 331 | 387 | 311 | -119 | -206 | -246 | -234 | -220 | -149 | -150 |
Working Capital Days | 101 | 554 | 317 | 325 | 409 | -37 | -57 | -99 | -79 | -94 | -69 | -77 |
ROCE % | 10% | -4% | -10% | -20% | -14% | -4% | -4% | 2% | 8% | 11% | 8% |
Documents
Announcements
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
10 Apr - Update on merger of the company with Ind Swift Laboratories Limited (Group Company)
- Clarification On Price Movement 10 Apr
-
Clarification sought from Ind-Swift Ltd
10 Apr - Exchange has sought clarification from Ind-Swift Ltd on April 10, 2024, with reference to Movement in Price.
- Compliance Certificate As per Regulation 7(3) Of SEBI (LODR) Regulations, 2015 9 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Compliance under regulation 74(5) for quarter ended March 31, 2024
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Business Overview:[1]
Company has expertise in finished goods dosage, Active Pharmaceutical Ingredients (API’s) and herbal products. Company also diversified into multiple fields viz., Infrastructure, Printing, Packaging & Stationary, Education, and Media Publication with its every unit as an independent profit earning center